Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy Versus D064 or D702 Monotherapy

Summary

The purpose of this study is to evaluate the Efficacy and Safety of D064 and D702 Combination Therapy Versus D064 or D702 Monotherapy in Essential Hypertension Patients

Timeline

Start

2023-07-31

Primary completion

2024-03-22

Completion

2024-03-26

Outcome

Met primary endpoint

paper change in msSBP was -20.04 (1.46) mm Hg in the Tel/S-Amlo group, compared with -16.44 (1.46) mm Hg in the Tel group PMID 41672793 ↗

paper between-group difference -3.60 (1.78) mm Hg, P-value = 0.0451). PMID 41672793 ↗

paper Tel/S-Amlo group showed a change of -21.12 (1.33) mm Hg versus -15.58 (1.32) mm Hg in the S-Amlo group PMID 41672793 ↗

paper between-group difference -5.53 (1.61) mm Hg, P-value = 0.0008). PMID 41672793 ↗

Publications

• Lee SH, Park K, Lee KH, Cho Y, Kim DH, Lim S, Bo Yoon S, Jang JS, Lim HS, Doh JH, Kim DY, Sohn IS, Cheon DY, Bae MH, Kim SH, Lee Y, Ihm SH, Choi RK, Park HJ, Pyun WB, Choi S, Shin J. Efficacy and Safety of Combination Therapy With Low Dose of Telmisartan and S-Amlodipine in Patients With Hypertension: A Randomized, Double-Blind, Multicenter, Therapeutic Confirmatory, Phase III Clinical Trial. Clin Ther. 2026 Mar;48(3):240-246. doi: 10.1016/j.clinthera.2026.01.001. Epub 2026 Feb 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	D064	Unknown	20 mg	—
Subject	D702	Unknown	1.25 mg	—

Indications